Volume 22 Issue 5
May  2024
Turn off MathJax
Article Contents
JING Zhaohe, WANG Yingjie, MAI Yumiao, SUN Pan, DONG Pengpeng, LIU Jian. Acquired hemophilia following haploidentical hematopoietic stem cell transplantation for acute lymphoblastic leukemia in children: one case report and literature review[J]. Chinese Journal of General Practice, 2024, 22(5): 900-902. doi: 10.16766/j.cnki.issn.1674-4152.003530
Citation: JING Zhaohe, WANG Yingjie, MAI Yumiao, SUN Pan, DONG Pengpeng, LIU Jian. Acquired hemophilia following haploidentical hematopoietic stem cell transplantation for acute lymphoblastic leukemia in children: one case report and literature review[J]. Chinese Journal of General Practice, 2024, 22(5): 900-902. doi: 10.16766/j.cnki.issn.1674-4152.003530

Acquired hemophilia following haploidentical hematopoietic stem cell transplantation for acute lymphoblastic leukemia in children: one case report and literature review

doi: 10.16766/j.cnki.issn.1674-4152.003530
Funds:

 JC21854036

  • Received Date: 2023-04-19
    Available Online: 2024-07-20
  • Acquired hemophilia (AH) is a rare disease caused by autoantibodies against factors. We reported a case of acute lymphoblastic leukemia (T-lineage, high-risk) in a child who developed acquired hemophilia after haploidentical hematopoietic stem cell transplantation (paternal donor, HLA 5/10) and reviewed the relevant literature. Laboratory tests showed decreased coagulation factor Ⅸ activity (FⅨ: C), FⅪ: C, and FⅫ: C, and an elevated FⅨ inhibitor titer, which is rare the clinic. After diagnosis, the child was treated with methylprednisolone in combination with cyclosporine A. With improvement of symptoms, the patient was discharged and continued to take cyclosporine A and methylprednisolone regularly. Four months after discharge, symptoms recurred, and the treatment regimen was changed to double-dose methylprednisolone combined with cyclosporine A immunosuppressive therapy, and the child was discharged with improvement. There was no recurrence of symptoms until March 2023.

     

  • loading
  • [1]
    DELGADO J, JIMENEZ-YUSTE V, HERNANDEZ-NAVARRO F, et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors[J]. Br J Haematol, 2003, 121(1): 21-35. doi: 10.1046/j.1365-2141.2003.04162.x
    [2]
    KALOYANNIDIS P, SAKELLARI I, FASSAS A, et al. Acquired hemophilia-A in a patient with multiple sclerosis treated with autologous hematopoietic stem cell transplantation and interferon beta-1a[J]. Bone Marrow Transplant, 2004, 34(2): 187-188. doi: 10.1038/sj.bmt.1704550
    [3]
    LOZIER J N, NGHIEM K, LEE M, et al. Acquired haemophilia A after stem cell transplant for sickle cell disease: treatment with recombinant porcine factor (OBI-1) and tolerance induction with rituximab/prednisone[J]. Haemophilia, 2014, 20(2): e185-e188. doi: 10.1111/hae.12273
    [4]
    FAN Z P, LIU Q F, SUN J. Acquired haemophilia A after allogeneic stem cell transplant for acute myeloid leukemia: occurred during cyclosporin a used for chronic graft versus host disease and tolerance induction with rituximab[J]. Blood, 2014, 124(21): 3. doi: 10.1182/blood.V124.21.3.3
    [5]
    DE LANGHE E, LENAERTS J, DIERICKX D, et al. Acquired haemophilia A in a patient with systemic sclerosis treated with autologous haematopoietic stem cell transplantation[J]. Rheumatology (Oxford), 2015, 54(1): 196-197. doi: 10.1093/rheumatology/keu402
    [6]
    JONES L, DANDOY C, JODELE S, et al. Successful management of concurrent acquired hemophilia A and a lupus anticoagulant in a pediatric hematopoietic stem cell transplant patient[J]. Bone Marrow Transplant, 2018, 53(4): 487-489. doi: 10.1038/s41409-017-0041-0
    [7]
    焦雪丽, 王勇奇, 艾昊, 等. 单倍型造血干细胞移植后合并移植后淋巴组织增殖性疾病及获得性血友病一例报告并文献复习[J]. 中华血液学杂志, 2019, 40(8): 691-693.

    JIAO X L, WANG Y Q, AI H, et al. Post- transplantation lymphoproliferative disorder accompanies acquired hemophilia after haploid hematopoietic stem cell transplantation in a pediatric AML patient: a case report and literature review[J]. Chinese Journal of Hematology, 2019, 40(8): 691-693.
    [8]
    UMINSKI K, KHALIFE R, KEKRE N, et al. Acquired hemophilia A following allogeneic stem cell transplantation for acute lymphoblastic leukemia[J]. Ann Hematol, 2022, 101(8): 1861-1863. doi: 10.1007/s00277-022-04819-6
    [9]
    TIEDE A, COLLINS P, KNOEBL P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A[J]. Haematologica, 2020, 105(7): 1791-801. doi: 10.3324/haematol.2019.230771
    [10]
    兰秋丽, 李慧, 宁俞智, 等. 典型围产期获得性血友病甲1例报告及文献复习[J]. 中华全科医学, 2020, 18(9): 1609-1611. doi: 10.16766/j.cnki.issn.1674-4152.001573

    LAN Q L, LI H, NING Y Z, et al. A case report and literature review of typical perinatal acquired hemophilia A[J]. Chinese Journal of General Practice, 2020, 18(9): 1609-1611. doi: 10.16766/j.cnki.issn.1674-4152.001573
    [11]
    KRUSE-JARRES R, KEMPTON C L, BAUDO F, et al. Acquired hemophilia A: updated review of evidence and treatment guidance[J]. Am J Hematol, 2017, 92(7): 695-705. doi: 10.1002/ajh.24777
    [12]
    中华医学会血液学分会血栓与止血学组, 中国血友病协作组. 获得性血友病A诊断与治疗中国指南(2021年版)[J]. 中华血液学杂志, 2021, 42(10): 793-799. doi: 10.3760/cma.j.issn.0253-2727.2021.10.001

    Thrombosis and Hemostasis Group, Chinese Society of HematologyChinese Medical Association; Hemophilia Treatment Center Collaborative Network of China. Chinese guidelines on the diagnosis and treatment of acquired hemophilia A (2021)[J]. Chinese Journal of Hematology, 2021, 42(10): 793-799. doi: 10.3760/cma.j.issn.0253-2727.2021.10.001
    [13]
    KNOEBL P, THALER J, JILMA P, et al. Emicizumab for the treatment of acquired hemophilia A[J]. Blood, 2021, 137(3): 410-419. doi: 10.1182/blood.2020006315
    [14]
    SUN B, XUE F, FENG Y, et al. Outcome of CARE: a 6-year national registry of acquired haemophilia A in China[J]. Br J Haematol, 2019, 187(5): 653-665. doi: 10.1111/bjh.16128
    [15]
    MINGOT-CASTELLANO M E, PARDOS-GEA J, HAYA S, et al. Management of acquired hemophilia A: results from the Spanish registry[J]. Blood Adv, 2021, 5(19): 3821-3829. doi: 10.1182/bloodadvances.2021004626
    [16]
    SIMON B, CEGLEDI A, DOLGOS J, et al. Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen[J]. Blood, 2022, 140(18): 1983-1992. doi: 10.1182/blood.2022016873
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Article Metrics

    Article views (26) PDF downloads(2) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return